A Randomized Phase II Study of PEP02, Irinotecan or Docetaxel as a Second Line Therapy in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.

Trial Profile

A Randomized Phase II Study of PEP02, Irinotecan or Docetaxel as a Second Line Therapy in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2013

At a glance

  • Drugs Irinotecan (Primary) ; Docetaxel
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 01 Mar 2012 Actual end date (December 2010) added as reported by ClinicalTrials.gov.
    • 25 Jan 2011 Results presented at the 2011 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ACSO), according to a PharmaEngine media release
    • 25 Jan 2011 Primary endpoint 'Objective-clinical-response-rate' has been met
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top